EP 7

FDA Roadmap: Reducing Animal Testing in Preclinical Studies

The FDA proposes a roadmap to reduce animal testing in preclinical studies, aiming to improve drug development efficiency and accuracy. This episode discusses the limitations of traditional animal testing and the potential of new approach methodologies (NAMs) like in vitro human-based systems and in silico modeling. The FDA's plan to implement NAMs and the challenges ahead are also explored.

FDAanimal testingpreclinical studiesnew approach methodologiesin vitro human-based systemsin silico modeling

play_arrowListen to episode

Key Concepts

New Approach Methodologies (NAMs)

In vitro human-based systems, such as organoids and organs on chips
In silico modeling, including computational modeling and AI
Ex vivo human tissue testing
High-throughput cell-based screening
Microdosing in human volunteers

In Vitro Human-Based Systems

Organoids: mini organs grown in a dish
Organs on chips: microfluidic chips with human cells
Reconstructed human skin models

In Silico Modeling

Computational modeling, including PBPK modeling
AI and machine learning for predicting toxicity and efficacy
Quantitative systems pharmacology (QSP) models

FDA Implementation Plan

Encouraging parallel submissions of NAM data
Developing a database of toxicity data
Reducing animal testing durations for MABs and other drugs
Tracking progress and validating NAMs

Challenges and Hurdles

Gap analysis: identifying key safety questions for different drug types
NAM development: improving organ models and expanding toxicity databases
Standardization and reproducibility: ensuring consistent results across labs

Episode Summary

check_circleThe FDA proposes a roadmap to reduce animal testing in preclinical studies
check_circleTraditional animal testing has limitations, with over 90% of drugs failing in human trials
check_circleNew approach methodologies (NAMs) like in vitro human-based systems and in silico modeling offer potential alternatives
check_circleThe FDA plans to implement NAMs, starting with monoclonal antibodies (MABs)
check_circleNAMs could reduce animal testing, improve accuracy, and decrease costs
check_circleThe FDA will track progress, validate NAMs, and update regulations to incorporate NAMs
check_circleThe long-term goal is to make animal studies the exception, not the rule, and replace them with NAMs
check_circleScientific and technical hurdles need to be addressed, including gap analysis, NAM development, and standardization

Full Transcript

Discussion

Join the discussion — sign in to leave a comment.